2MG6
 
 | | Non-reducible analogues of alpha-conotoxin Vc1.1: [3,16]-trans dicarba Vc1.1 | | Descriptor: | Alpha-conotoxin Vc1A | | Authors: | Robinson, S.D, Macraild, C.A, Van Lierop, B.J, Robinson, A.J, Norton, R.S. | | Deposit date: | 2013-10-28 | | Release date: | 2013-12-18 | | Method: | SOLUTION NMR | | Cite: | Dicarba alpha-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors.
Acs Chem.Biol., 8, 2013
|
|
2MFY
 | | Non-reducible analogues of alpha-conotoxin Vc1.1: [2,8]-trans dicarba Vc1.1 | | Descriptor: | Alpha-conotoxin Vc1A | | Authors: | Robinson, S.D, Macraild, C.A, Van Lierop, B.J, Robinson, A.J, Norton, R.S. | | Deposit date: | 2013-10-24 | | Release date: | 2013-12-18 | | Method: | SOLUTION NMR | | Cite: | Dicarba alpha-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors.
Acs Chem.Biol., 8, 2013
|
|
2MFX
 | | Non-reducible analogues of alpha-conotoxin Vc1.1: [2,8]-cis dicarba Vc1.1 | | Descriptor: | Alpha-conotoxin Vc1A | | Authors: | Robinson, S.D, Macraild, C.A, Van Lierop, B.J, Robinson, A.J, Norton, R.S. | | Deposit date: | 2013-10-24 | | Release date: | 2013-12-18 | | Method: | SOLUTION NMR | | Cite: | Dicarba alpha-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors.
Acs Chem.Biol., 8, 2013
|
|
2N24
 | |
7R6P
 | |
5KKM
 | | Con-Vc11-22 | | Descriptor: | O2_contryphan_Vc1 prepropeptide | | Authors: | Chittoor, B, Krishnarjuna, B, MacRaild, C.A, Robinson, S.D. | | Deposit date: | 2016-06-22 | | Release date: | 2017-05-31 | | Last modified: | 2023-06-14 | | Method: | SOLUTION NMR | | Cite: | The Single Disulfide-Directed beta-Hairpin Fold. Dynamics, Stability, and Engineering.
Biochemistry, 56, 2017
|
|
2MTO
 | | Non-reducible analogues of alpha-conotoxin RgIA: [2,8]-cis dicarba RgIA | | Descriptor: | Alpha-conotoxin RgIA | | Authors: | Chhabra, S, Robinson, S, Norton, R. | | Deposit date: | 2014-08-26 | | Release date: | 2014-11-26 | | Last modified: | 2023-06-14 | | Method: | SOLUTION NMR | | Cite: | Dicarba Analogues of alpha-Conotoxin RgIA. Structure, Stability, and Activity at Potential Pain Targets.
J.Med.Chem., 57, 2014
|
|
2MTT
 | | Non-reducible analogues of alpha-conotoxin RgIA: [3,12]-cis dicarba RgIA | | Descriptor: | Dicarba Analogues of alpha-Conotoxin RgIA | | Authors: | Chhabra, S, Robinson, S.D, Norton, R.S. | | Deposit date: | 2014-08-31 | | Release date: | 2014-11-26 | | Last modified: | 2023-12-27 | | Method: | SOLUTION NMR | | Cite: | Dicarba Analogues of alpha-Conotoxin RgIA. Structure, Stability, and Activity at Potential Pain Targets.
J.Med.Chem., 57, 2014
|
|
1E3B
 | | CYCLOPHILIN 3 FROM C.ELEGANS COMPLEXED WITH AUP(ET)3 | | Descriptor: | CYCLOPHILIN 3, GOLD ION, TRIETHYLPHOSPHANE | | Authors: | Zou, J, Taylor, P, Dornan, J, Robinson, S.P, Walkinshaw, M.D, Sadler, P.J. | | Deposit date: | 2000-06-08 | | Release date: | 2000-10-22 | | Last modified: | 2019-05-22 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | First Crystal Structure of a Medicinally Relevant Gold Protein Complex:Unexpected Binding of [Au(Pet (3))](+) to Histidine
Angew.Chem.Int.Ed.Engl., 39, 2000
|
|
2MTU
 | | Non-reducible analogues of alpha-conotoxin RgIA: [3,12]-trans dicarba RgIA | | Descriptor: | Dicarba Analogues of alpha-Conotoxin RgIA | | Authors: | Chhabra, S, Robinson, S.D, Norton, R.S. | | Deposit date: | 2014-09-01 | | Release date: | 2014-11-26 | | Last modified: | 2023-12-27 | | Method: | SOLUTION NMR | | Cite: | Dicarba Analogues of alpha-Conotoxin RgIA. Structure, Stability, and Activity at Potential Pain Targets.
J.Med.Chem., 57, 2014
|
|
5F4N
 | | Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737) | | Descriptor: | 1,2-ETHANEDIOL, GLYCEROL, Serine/threonine-protein kinase Chk1, ... | | Authors: | Collins, I, Garrett, M.D, van Montfort, R, Osborne, J.D, Matthews, T.P, McHardy, T, Proisy, N, Cheung, K.J, Lainchbury, M, Brown, N, Walton, M.I, Eve, P.D, Boxall, K.J, Hayes, A, Henley, A.T, Valenti, M.R, De Haven Brandon, A.K, Box, G, Westwood, I.M, Jamin, Y, Robinson, S.P, Leonard, P, Reader, J.C, Aherne, G.W, Raynaud, F.I, Eccles, S.A. | | Deposit date: | 2015-12-03 | | Release date: | 2016-05-25 | | Last modified: | 2016-06-22 | | Method: | X-RAY DIFFRACTION (1.91 Å) | | Cite: | Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J.Med.Chem., 59, 2016
|
|
7KNN
 | |
